Resistance training and total and site-specific cancer risk: a prospective cohort study of 33,787 US men

Imagem de Miniatura
Citações na Scopus
Tipo de produção
Data de publicação
Título da Revista
ISSN da Revista
Título do Volume
LEE, Dong Hoon
WU, Kana
BRITISH JOURNAL OF CANCER, v.123, n.4, p.666-672, 2020
Projetos de Pesquisa
Unidades Organizacionais
Background Muscle-strengthening activities have been recommended for health benefits. However, it is unclear whether resistance training is associated with cancer risk, independent of total physical activity. Methods A prospective cohort study followed 33,787 men from the Health Professionals Follow-up Study (1992-2014). Cumulative average of resistance training (hours/week) was assessed through biennial questionnaires up to 2 years before cancer diagnosis. Cox regression model was used to estimate the hazard ratio (HR) and 95% confidence intervals (CI). Results During 521,221 person-years of follow-up, we documented 5,158 cancer cases. Resistance training was not associated with total cancer risk (HR per 1-h/week increase: 1.01; 95% CI 0.97, 1.05). We found an inverse association between resistance training and bladder cancer (HR per 1-h/week increase: 0.80; 95% CI 0.66, 0.96) and kidney cancer (HR per 1-h/week increase 0.77; 95% CI 0.58, 1.03; P-trend = 0.06), but the association was marginal for the latter after adjustment for confounders and total physical activity. Compared to participants engaging in aerobic activities only, combined resistance training and aerobic activities showed stronger inverse associations with kidney cancer risk. Conclusions Resistance training was associated with lower risk of bladder and kidney cancers. Future studies are warranted to confirm our findings.
  1. Ainsworth BE, 2011, MED SCI SPORT EXER, V43, P1575, DOI 10.1249/MSS.0b013e31821ece12
  2. [Anonymous], 2018, 2018 PHYS ACT GUID A
  3. Chiuve SE, 2012, J NUTR, V142, P1009, DOI 10.3945/jn.111.157222
  4. Cornelissen VA, 2013, J AM HEART ASSOC, V2, DOI 10.1161/JAHA.112.004473
  5. Giovannucci E, 2010, CA-CANCER J CLIN, V60, P207, DOI 10.3322/caac.20078
  6. Grontved A, 2012, ARCH INTERN MED, V172, P1306, DOI 10.1001/archinternmed.2012.3138
  7. Hojman P, 2018, CELL METAB, V27, P10, DOI 10.1016/j.cmet.2017.09.015
  8. Hutcheon JA, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2289
  9. Keum N, 2016, JAMA ONCOL, V2, P1146, DOI 10.1001/jamaoncol.2016.0740
  10. Lauby-Secretan B, 2016, NEW ENGL J MED, V375, P794, DOI 10.1056/NEJMsr1606602
  11. Lee DH, 2019, INT J CANCER, V145, P360, DOI 10.1002/ijc.32111
  12. de Rezende LFM, 2018, BRIT J SPORT MED, V52, P826, DOI 10.1136/bjsports-2017-098391
  13. Mahabir S, 2018, CANCER EPIDEM BIOMAR, V27, P233, DOI 10.1158/1055-9965.EPI-17-0509
  14. Mazzilli KM, 2019, MED SCI SPORT EXER, V51, P1845, DOI 10.1249/MSS.0000000000001987
  15. Moore SC, 2016, JAMA INTERN MED, V176, P816, DOI 10.1001/jamainternmed.2016.1548
  16. Mucci LA, 2020, JNCI-J NATL CANCER I, V112, P5, DOI 10.1093/jnci/djz102
  17. Patel AV, 2019, MED SCI SPORT EXER, V51, P2391, DOI 10.1249/MSS.0000000000002117
  18. RIMM EB, 1992, AM J EPIDEMIOL, V135, P1114, DOI 10.1093/oxfordjournals.aje.a116211
  19. Tanasescu N, 2002, JAMA-J AM MED ASSOC, V288, P1994, DOI 10.1001/jama.288.16.1994
  20. World Cancer Research Fund, 2018, DIET NUTR PHYS ACT C